Available Until 10/18/2022

Infectious Diseases Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L229120)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/16/2022
Content Release Date: 04/13/2022
Expiration Dates: 10/18/2022
Activity Type: Application-based
CE Credits: 10 contact hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A: HIV and Sexually Transmitted Infections: This module focuses on the treatment of HIV infection. Guidelines on the treatment of sexually transmitted infections are also included, focusing on gonorrhea and chlamydia. 

Module 1B: Treatment Challenges in Gram-Negative Bacterial Infections and Prosthetic Joint Infections: This module focuses on the treatment of gram negative infections, including those caused by antibiotic-resistant bacteria. In addition, the optimal duration of treatment of prosthetic joint infections is considered. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS. 

The American Society of Health-System Pharmacists and American College of Clnical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours through the Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete these assessments.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Infectious Diseases Pharmacy Literature Study Module 1A: HIV and Sexually Transmitted Infections

0204-9999-22-946-H01-P

4.0

75%

Infectious Diseases Pharmacy Literature Study Module 1B: Treatment Challenges in Gram-Negative Bacterial Infections and Prosthetic Joint Infections

0204-9999-22-947-H01-P

6.0

71%

Module 1A: HIV and Sexually Transmitted Infections
ACPE Number: 0204-9999-22-946-H01-P

This module focuses on the treatment of HIV infection. Guidelines on the treatment of sexually transmitted infections are also included, focusing on gonorrhea and chlamydia. 

Saag MS. HIV infection — screening, diagnosis, and treatment. N Engl J Med. 2021; 384(22):2131-2143.

Learning Objectives:

  • Describe the screening, diagnosis, and treatment of HIV infection.
  • Develop recommendations for the screening, diagnosis, and treatment of HIV infection.

Overton ET, Richmond G, Rizzardiini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020; 396(10267):1994-2005.

Learning Objectives:

  • Describe the ATLAS-2M study by Overton and colleagues.
  • Develop recommendations for maintenance viral suppressive therapy in patients living with HIV-1 infection with viral suppression.

Workowski KA, Bachmann LH, Chan PA et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021; 70(4): 1-192.
(IMPORTANT: For this Literature Study, only pages 65-80 [chlamydia and gonorrhea] are assessed.)

Learning Objectives:

  • Describe the 2021 Centers for Disease Control and Prevention (CDC) treatment guidelines for sexually transmitted infections involving Chlamydia trachomatis and Neisseria gonorrhoeae.
  • Develop recommendations for screening for and treating chlamydial and gonococcal infections.

Module 1B: Treatment Challenges in Gram-Negative Bacterial Infections and Prosthetic Joint Infections
ACPE Number: 0204-9999-22-947-H01-P

This module focuses on the treatment of gram negative infections, including those caused by antibiotic-resistant bacteria. In addition, the optimal duration of treatment of prosthetic joint infections is considered. 

Tamma PD, Aitken SL, Bonomo RA et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):1109-1116.

Learning Objectives:

  • Describe the Infectious Diseases Society of America (IDSA) guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
  • Develop recommendations for the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).

Bassetti M, Echols R, Matsunaga Y et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021; 21(2):226-240.

Learning Objectives:

  • Describe the CREDIBLE-CR study by Bassetti and colleagues of cefiderocol for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria.
  • Develop recommendations for the use of cefiderocol to treat adults with serious carbapenem-resistant gram-negative bacterial infections.

Falcone M, Daikos GL, Tiseo G et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase–producing Enterobacterales. Clin Infect Dis.2021; 72(11):1871–1878.

Learning Objectives:

  • Describe the study by Falcone and colleagues comparing ceftazidime-avibactam (CAZ-AVI) plus aztreonam (ATM) with other active antibiotics in patients with bloodstream infections (BSIs) caused by metallo-β-lactamase (MBL)-producing Enterobacterales.
  • Develop recommendations for the treatment of adults with bloodstream infections (BSIs) caused by metallo-β-lactamase (MBL)-producing Enterobacterales.

Sutton JD, Stevens VW, Chang NC et al. Oral β-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source. JAMA Netw Open. 2020; 3(10):e2020166.
(IMPORTANT: Information contained in the Supplement is also assessed.)

Learning Objectives:

  • Describe the study by Sutton and colleagues comparing oral β-lactam antibiotics with a fluoroquinolone or trimethoprim-sulfamethoxazole for the treatment of Enterobacterales bacteremia with a suspected urinary source.
  • Develop recommendations for the treatment of adults with Enterobacterales bacteremia with a suspected urinary source.

Bernard L, Arvieux C, Brunschweiler B et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med. 2021; 384:1991-2001.

Learning Objectives:

  • Describe the Duration of Antibiotic Treatment in Prosthetic Joint Infection (DATIPO) study by Bernard and colleagues.
  • Develop recommendations for antibiotic therapy for patients with microbiologically confirmed prosthetic joint infections managed with standard surgical procedures.

Full Faculty Bios

Samuel L. Aitken, Pharm.D., M.P.H., BCIDP
Clinical Pharmacist Specialist - Infectious Diseases
University of Michigan Health
Ann Arbor, Michigan 

Dana R.  Bowers, Pharm.D., BCIDP, BCPS (AQ-ID)
Clinical Assistant Professor
Washington State University College of Pharmacy and Pharmaceutical Sciences
Yakima, Washington 

Julie Harting, Pharm.D., BCIDP
Associate Professor / Clinical Pharmacist Specialist
Sullivan University College of Pharmacy and Health Sciences / U of L Health
Louisville, Kentucky 

Neha Sheth Pandit, Pharm.D., BCPS, AAHIVP
Associate Professor
University of Maryland School of Pharmacy
Baltimore, Maryland 

Content Matter Experts

Kevin W. Garey, Pharm.D., M.S., FASHP, FIDSA
Professor and Chair
University of Houston
Houston, Texas 

Jason J. Schafer,Pharm.D., M.P.H., BCPS, BCIDP, AAHIVP, FASHP
Professor and Vice Chair, Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Kayla R. Stover, Pharm.D., BCPS, BCIDP, FCCP, FIDSA
Associate Professor
University of Mississippi School of Pharmacy
Madison, Mississippi 

Evan Zasowski, Pharm.D., M.P.H., BCPS, BCIDP
Assistant Professor, Department of Clinical Sciences
Touro University California College of Pharmacy
Vallejo, California

Susan R. Dombrowski, M.S., RPh
Kristi Hofer, Pharm.D.

Hakeem Abayomi, B.S., Pharm.D., BCPS, BCPPS, BCIDP
Alaa Ali Ahmed Ali, B.S., Pharm.D., BCCCP, BCIDP
Hanan Alshareef, Pharm.D., BCPS, BCIDP
Jill Argotsinger, Pharm.D., BCIDP
Lauren Biehle, Pharm.D., BCPS, BCIDP
Maria  Coccimiglio, B.S.Pharm., BCIDP
Joanna DeAngelis, Pharm.D., BCIDP
Jonathan Edwards, Pharm.D., BCPS, BCGP, BCIDP
Heba Eldash, BCIDP
Dina Elsebaei, Pharm.D., BCIDP
Jimmy El-Yamani, R.Ph., BCIDP
Jessica  Foley, Pharm.D., BCIDP
Elhussein  Ghoneim, MSC, BCIDP
Fischer Herald, Pharm.D., BCIDP, AAHIVP
Melanie Hyte, Pharm.D., BCIDP
Daniel Ilges, Pharm.D., BCIDP
Alison Ivey, Pharm.D., BCPS, BCIDP
Jamie Legaspi, Pharm.D., BCIDP
Rosanna Li, Pharm.D., BCIDP
Rama Nasef, Pharm.D., BCIDP
Kelcey Noble, B.S., Pharm.D., BCPIDP
Natasha Pettit, Pharm.D., BCIDP
Kamryn  Plechot, Pharm.D., BCIDP
Anna Poston-Blahnik, Pharm.D., BCIDP
Stephon Poulton, Pharm.D., BCPS, BCIDP
Yinghui PU, Pharm.D., Ph.D., BCPS, BCIDP
Lauren Puckett, Pharm.D., BCIDP
Julia Sapozhnikov, Pharm.D., BCIDP
Jessica Sobnosky, Pharm.D., BCPS, BCIDP
Danita Stead, Pharm.D., BCIDP
Abrar Thabit, Pharm.D., BCIDP
Riley Williams II, Pharm.D., BCIDP
Xhilda Xhemali, Pharm.D., BCIDP
Arsheena Yassin, Pharm.D., BCIDP, AAHIVP
Salah Zouein, Pharm.D., BCIDP, BCCCP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP and ACCP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  •          Complete the attestation statement
  •          Review all content
  •          Complete and pass the assessments
  •          Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

These activities were developed by ASHP and ACCP.